Results 91 to 100 of about 31,353 (262)
Movement Disorders, EarlyView.Abstract Background Parkinson's disease (PD) is characterized by predominantly neuronal α‐synuclein pathology and dopaminergic dysfunction. Cerebrospinal fluid (CSF) seeding amplification assays (SAA) detect α‐synuclein aggregates in vivo, but not all patients with PD have a positive SAA.
Michael Tran Duong +186 more
wiley +1 more source
Tau phosphorylation at Alzheimer\u27s disease-related Ser356 contributes to tau stabilization when PAR-1/MARK activity is elevated. [PDF]
, 2016 Abnormal phosphorylation of the microtubule-associated protein tau is observed in many neurodegenerative diseases, including Alzheimer\u27s disease (AD).
Ando, Kanae +6 more
core +1 more source
Movement Disorders, EarlyView.Abstract Background The cerebrospinal fluid alpha‐synuclein seed amplification assay (CSFasynSAA) detects alpha‐synuclein aggregation in over 90% of individuals with sporadic PD (sPD). However, the clinical characteristics of sPD with negative CSFasynSAA remain undefined.
Sarah M. Brooker +30 more
wiley +1 more source
TREM2-dependent effects on microglia in Alzheimer\u27s Disease [PDF]
, 2018 Alzheimer’s disease (AD) is a late-onset dementia characterized by the deposition of amyloid plaques and formation of neurofibrillary tangles (NFTs) which lead to neuronal loss and cognitive deficits.
Colonna, Marco +2 more
core +3 more sources
Brain Pathology, EarlyView.We investigated neuropathological manifestations of hypothermia in 168 cases. Patients aged 65 years or more constituted 80% of the total cohort. Alzheimer's disease was the most common comorbidity, affecting 40% of all patients. Abstract There is a paucity of autopsy‐based studies providing detailed neuropathological characteristics of fatal ...
Shojiro Ichimata +2 more
wiley +1 more source
Experimental GerontologyReducing neuroinflammation, a key contributor to brain aging and neurodegenerative diseases, is a promising strategy for improving cognitive function in these settings. The FDA-approved nucleoside reverse transcriptase inhibitor 3TC (Lamivudine) has been
Devin Wahl +2 more
doaj +1 more source
A small molecule ApoE4-targeted therapeutic candidate that normalizes sirtuin 1 levels and improves cognition in an Alzheimer's disease mouse model. [PDF]
, 2018 We describe here the results from the testing of a small molecule first-in-class apolipoprotein E4 (ApoE4)-targeted sirtuin1 (SirT1) enhancer, A03, that increases the levels of the neuroprotective enzyme SirT1 while not affecting levels of neurotoxic ...
Bai, Dongsheng +14 more
core +3 more sources
Brain Pathology, EarlyView.The study analyzed the seeding activity of misfolded tau protein in Alzheimer's disease and rapidly progressive Alzheimer's disease patients and provides evidence for the existence of different tau assemblies supported by differences in cellular toxicity and morphology of thioflavin T‐positive real‐time quaking‐induced conversion products.
Matthias Schmitz +13 more
wiley +1 more source
Frontiers in Cellular Neuroscience, 2019 The microtubule-associated protein tau (MAPT) is mainly identified as a tubulin binding protein essential for microtubule dynamics and assembly and for neurite outgrowth.
Rafaella Araujo Gonçalves +7 more
doaj +1 more source
Brain Pathology, EarlyView.The efficacy of the novel anti‐tau active immunotherapy, p5555kb, was tested using two mouse models of tau pathology. p5555kb inoculation increased the survival rate and reduced tau pathology in tau‐overexpressing P301L mice and decreased tau seeding in the brains of C57BL/6 mice injected with human‐purified Alzheimer's disease tau.
Christopher M. Brown +7 more
wiley +1 more source